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Peroxisomeproliferator-activatedreceptors(PPARs)aretranscriptionfactorsthatactaslipidsensorsandadaptthemetabolicrates
of various tissues to the concentration of dietary lipids. PPARs are pharmacological targets for the treatment of metabolic disor-
ders.PPARαandPPARγ areactivatedbyhypolipidemicandinsulin-sensitizercompounds,suchasﬁbratesandthiazolidinediones.
The roles of PPARβ/δ in metabolic regulations remained unclear until recently. Treatment of obese monkeys and rodents by spe-
ciﬁc PPARβ/δ agonists promoted normalization of metabolic parameters and reduction of adiposity. Recent evidences strongly
suggested that some of these beneﬁcial actions are related to activation of fatty acid catabolism in skeletal muscle and also that
PPARβ/δ is involved in the adaptive responses of skeletal muscle to environmental changes, such as long-term fasting or physical
exercise, by controlling the number of oxidative myoﬁbers. These observations indicated that PPARβ/δ agonists might have ther-
apeutic usefulness in metabolic syndrome by increasing fatty acid consumption in skeletal muscle and reducing obesity.
Copyright © 2007 C. Gaudel and P. A. Grimaldi. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
The prevalence of adult obesity and obesity-associated
metabolic disorders, including insulin resistance, glucose in-
tolerance, hypertension, and dyslipidemia, has reached epi-
demic proportions in industrialized countries. The causes
of the increase of this cluster of pathologies, known as the
metabolic syndrome, are multiple and not totally elucidated.
However, it is accepted that environmental factors, such as
excess of food intake and lack of physical exercise, that char-
acterize western lifestyle and lead to lipid homeostasis im-
balance, are major contributors in the development of these
pathologies. Lipid homeostasis requires a strict equilibrium
between lipid availability and lipid consumption. In the nor-
mal situation, fatty acids coming either from food or from
hepatic lipogenesis are utilized as energetic substrates in
heart and skeletal muscles. Adipose tissue plays a central role
in lipid homeostasis and can manage a transient increase in
lipid availability by increasing the amount of stored triacyl-
glycerol. However, long-term excess of dietary lipids and/or
decrease of energy expenditure create a profound distur-
bance in this physiological equilibrium leading to a perma-
nent increase in fatty acid availability and, on a long-term
basis, to accumulation of triacylglycerol and other lipids in
various tissues, such as adipose, liver, pancreas, and skele-
tal muscle. Such a lipid deposition leads to impairment of
insulin responsiveness and metabolic dysfunction [1]. Dur-
ing the last decade, it has been demonstrated that adipocyte
hypertrophy, a typical hallmark of adult obesity, results in
a profound alteration of adipokine production and impairs
the normal crosstalk between adipose tissue and the other
organs increasing the metabolic disorders [2]. Several evi-
dences clearly indicated that reducing lipid contents in blood
and insulin-sensitive tissues is a crucial challenge to prevent
metabolic syndrome. To reach this goal, lifestyle interven-
tion has been shown to be an eﬃcient strategy. For instance,
weight loss, leading to a normalization of adipocyte size and
adipokine secretion, and recurring physical exercise, pro-
moting increment of energy expenditure in skeletal muscle
and heart, have strong beneﬁcial eﬀects on insulin resistance
and type 2 diabetes in human [3]. Because changing western
lifestyle is very doubtful, pharmaceutical approaches mim-
icking the metabolic actions of weight loss and/or physical
exercise should be of great interest. During the last 15 years,
our knowledge of the molecular basis of lipid homeostasis
regulation has been considerably improved and numerous2 PPAR Research
studieshaveparticularlydemonstratedtherolesoftheperox-
isomeproliferator-activatedreceptors(PPARs)inthecontrol
of lipid metabolism, providing new ideas about the pharma-
cological treatment of metabolic syndrome.
2. PPARs: LIPID-ACTIVATED TRANSCRIPTION
FACTORS AND REGULATORS OF
LIPID METABOLISM
PPARs are ligand-activated transcription factors that be-
long to the nuclear receptor superfamily and play multiple
physiological roles in several tissues. Three PPAR isotypes,
α (NR1C1), β/δ (NR1C2), and γ (NR1C3), have been de-
scribed so far. Each of the PPAR isotypes is encoded in a
separate gene and exhibits tissue-selective expression pat-
terns.PPARαismainlyexpressedinliver,heart,kidney,small
intestine, and brown adipose tissue [4]. Several forms of
PPARγ have been identiﬁed with distinct expression pat-
terns. PPARγ2 is almost exclusively found in white and
brown adipose tissues, while PPARγ1 is expressed in several
other tissues and cell types including intestine, placenta, and
macrophages [5]. PPARβ/δ has a broad expression pattern in
adultmammals,butitisabundantlyexpressedinsmallintes-
tine, skeletal and cardiac muscles, brain, and adipose tissue
[6, 7].
PPARs are organized in diﬀerent domains. The amino-
terminal domain is poorly conserved between the three
isotypes and contains a ligand-independent transactivation
function. The central domain, which is highly conserved,
brings the capacity of DNA binding. The carboxyl-terminal
region contains the ligand-binding domain and confers
the ligand-dependent transactivation function. X-ray crystal
structure analyses have revealed some important diﬀerences
in the ligand-binding pocket of PPAR isotypes [8, 9]. These
diﬀerences explain why PPAR isotypes can bind a large di-
versity of molecules and also display a relative selectivity for
both natural and synthetic ligands.
PPARs heterodimerize with the retinoid X receptor (R-
XR, NR2B) and bind to a speciﬁc DNA responsive element,
called peroxisome proliferator response element (PPRE),
found in a large number of genes encoding proteins involved
in a variety of functions, including lipid and carbohydrate
metabolisms, inﬂammation, cell proliferation, and diﬀeren-
tiation [10, 11].
An important mark of PPAR transcriptional regulation
is the interaction with cofactors. The unliganded PPAR/RXR
heterodimer interacts with corepressors that exert transcrip-
tional repression. It has been proposed that binding of the
ligand promotes a conformational change that is permissive
for interactions with coactivator proteins allowing nucleo-
someremodelingandactivationofthetranscriptionoftarget
genes[8,12].Severalcorepressorsandcoactivatorsabletoin-
teract in a selective manner with the various PPAR isotypes
havebeendescribed.Someofthesecofactorsareexpressedin
a tissue-speciﬁc manner and are controlled by physiological
status in a given tissue. This selectivity of interaction could
explain the diﬀerential tissue-speciﬁc transcriptional activi-
ties of the various PPARs and the activity level of a speciﬁc
isotype depending upon the expression level of the cofactors
in a given tissue or physiological situation.
It is now established that PPARs are lipid sensors and
adapt the metabolic rates of various tissues to the concen-
tration of dietary lipids. This role is related to the capacity of
the various PPAR isotypes to bind fatty acids and fatty acid
derivatives and to regulate the expression of several genes
implicated in fatty acid uptake, handling, and metabolism
in various tissues. Long-chain fatty acids, either saturated
or unsaturated, appeared almost equally active for the three
PPAR isotypes and, interestingly, the metabolism of the fatty
acid is not required, as 2-bromopalmitate, a nonmetabolized
fatty acid, appeared to be a potent PPAR agonist in preadi-
pose cells [13].
SeveralfattyacidderivativeshavebeenshowntobePPAR
agonists. These molecules appeared to be more selective for
the PPAR isotypes than fatty acids. For instance, the 15-
deoxy-Δ12,14-PGJ2 (15d-PGJ2) is a selective PPARγ agonist
[14], leukotriene B4 and oleylethanolamide are activating se-
lectively the α isotype [15, 16], and the prostacyclin is more
active on PPARβ/δ than on the other isotypes [17]. However,
as it is not possible to estimate the actual concentrations of
fatty acids and fatty acid derivatives within the nuclear com-
partment,thephysiologicalimplicationofthesemoleculesas
endogenous PPAR ligands remains an open question.
Due to their potential therapeutic interest for the treat-
ment of metabolic disorders, several classes of PPAR syn-
thetic ligands have been developed. Fibrates, used from sev-
eral years as hypolididemic compounds, are speciﬁc lig-
ands/activators of PPARα [4]. Lipid lowering action of ﬁ-
brates is mainly due to their capacity to upregulate, through
PPARα activation, several genes involved in hepatic fatty
acid oxidation mimicking the eﬀects of fasting that increases
PPARα expression in liver [18].
Thiazolidinediones [19] that are potent and speciﬁc acti-
vators of the γ isotype are used as insulin sensitizers. This
action is paradoxically related to the adipogenic action of
PPARγ. It has been shown that thiazolidinediones promote a
remodeling of adipose tissue by the recruitment of new and
metabolically active adipocytes. These new adipocytes have
beneﬁcial eﬀects by increasing the storage capacity of fatty
acids and by normalizing adipokine secretion [20].
More recently, compounds able to speciﬁcally bind and
activatePPARβ/δ havebeendevelopedandithasbeenshown
that such compounds have beneﬁcial metabolic eﬀects in
obese animals [21, 22]. The availability of these potent and
speciﬁc agonists and the construction of appropriate cellular
and animal models revealedtheimportant rolesof this PPAR
isotypeinlipidmetabolism,especiallyinskeletalmuscle,and
pointed out the nuclear receptor as a potential target for the
pharmacological treatment of metabolic syndrome.
Many studies revealed that PPARβ/δ agonists could be
eﬀective compounds to normalize several biological param-
eters perturbed during metabolic syndrome. Some of these
studies were conducted by using the GW1516 compound
that activates PPARβ/δ at very low concentrations both in
vitro and in vivo with a 1000-fold selectivity over the other
PPAR isotypes [23]. An interesting study by Oliver et al. hasC. Gaudel and P. A. Grimaldi 3
evidenced the beneﬁcial actions of GW1516 administration
in insulin-resistant obese monkeys [21]. Indeed, a 4-week
treatment with the PPARβ/δ agonist increased high-density
lipoprotein cholesterol, decreased low-density lipoprotein
cholesterol,reducedthelevelsofsmallanddenselow-density
lipoproteins, and normalized insulin and triglyceride blood
levels. Moreover, it was reported that the same molecule re-
ducedadiposityandimprovedinsulinresponsivenessindiet-
induced and genetically obese mice [22, 24].
The mechanisms involved in these beneﬁcial actions of
PPARβ/δ agonist administration to obese animals are not
completely elucidated and, as the nuclear receptor is broadly
expressed, it is likely that these actions are involving several
tissues. However, during the last past years, several experi-
mental evidences coming from both cell culture and in vivo
studies have indicated that PPARβ/δ plays a central role in
theregulationoflipidmetabolismandadaptivedevelopment
in skeletal muscle and that responses of this tissue could ex-
plain some of the antidiabetic and lipid-lowering actions of
PPARβ/δ agonists in obese animals.
3. PPARβ/δ: REGULATORY ROLES IN MUSCLE
METABOLISM AND PHYSIOLOGY
PPARβ/δ is several-fold more abundant than the other PPAR
isotypes in rodent and human muscles [25]. Moreover, we
have shown that long-term fasting [26] and endurance train-
ing [27], two physiological situations characterized by an in-
crease in muscle fatty acid catabolism, increased PPARβ/δ
mRNAandproteincontentsinmouseskeletalmuscle.Asim-
ilar PPARβ/δ upregulation was observed in human muscle
after either long-term or short-term moderate exercise train-
ing [28–30].
Skeletal muscle accounts for about 40% of the body mass
and,inthistissue,energyexpenditure,insulinsensitivity,and
fuel preference are highly aﬀected by muscle work and my-
oﬁber composition [31, 32]. Depending upon their phys-
iological roles, the diﬀerent muscles contain variable per-
centages of speciﬁc myoﬁbers that diﬀer in both contrac-
tile and metabolic properties. Type 2b myoﬁbers express fast
isoforms of contractile proteins and synthesize ATP mainly
from anaerobic glycolysis. Type 2a myoﬁbers express fast
contractileproteins,butcontainmoremitochondria,andare
able to synthesize ATP from oxidation of glucose and fatty
acids. Type 1 myoﬁbers also have an oxidative metabolism
and express the slow isoforms of contractile proteins. For
instance, soleus muscle, which is implicated in endurance
works, contains almost exclusively type 1 and type 2a ox-
idative myoﬁbers, while the white gastrocnemius contains a
majority of type 2b glycolytic myoﬁbers and is implicated in
short-term and intense exercise. Importantly, the myoﬁber
composition of a given muscle is not ﬁxed and is modiﬁed
in some physiological or pathological situations. Endurance
training promotes a ﬁber-type transition in human and ro-
dents. In human muscle, moderate exercise induces a transi-
tionfromtype2btotype2aphenotype[33],whileamorein-
tense exercise is required for a transition toward type 1 phe-
notype [34]. Voluntary exercise increases type 2a myoﬁber
percentage in several mouse muscles with or without hy-
perplasia, that is, increment in total myoﬁber number [35].
Sedentary life and type 2 diabetes lead to the opposite phe-
notype with a reduction of oxidative phenotype of various
muscles [36, 37].
3.1. PPARβ/δ regulatesfattyacidburning
inskeletalmuscle
Muoio et al. reported that exposure of diﬀerentiated hu-
man or rat L6 myotubes to a highly selective PPARβ/δ ag-
onist or to a speciﬁc PPARα agonist equally increased fatty
acid oxidation and induced expression of several lipid reg-
ulatory genes, such as uncoupling protein 3 (UCP3), pyru-
vate dehydrogenase kinase 4 (PDK4), and carnitine palmi-
toyltransferase 1 (CPT1). These observations suggested a re-
dundancy in the regulatory functions of both PPAR isotypes
on fatty acid metabolism in cultured myotubes [38]. To di-
rectly establish the implication of PPARβ/δ in the control
of lipid metabolism in muscle cells, we conducted gain-of-
function and loss-of-function studies by overexpressing ei-
ther native or dominant negative forms of the nuclear recep-
tor in C2C12 myogenic cells. We showed that exposure of
diﬀerentiated C2C12 myotubes to 2-bromopalmitate, a non-
metabolized fatty acid, or to GW0742, a speciﬁc PPARβ/δ
agonist, upregulated expression of genes implicated in fatty
acid uptake, handling, and metabolism, such as Fatty Acid
Translocase (FAT/CD36), heart-Fatty Acid Binding Protein
(h-FABP), and CPT1. Furthermore, the direct implication of
PPARβ/δ in these regulations was established by the demon-
stration that the responses were, respectively, enhanced in
PPARβ/δ-overexpressing cells and almost completely abol-
ished in cells expressing the dominant negative form of
PPARβ/δ [26]. A microarray expression proﬁling study con-
ﬁrmed these ﬁndings and showed that in L6 myotubes, ac-
tivation of PPARβ/δ upregulated expression of a large panel
of genes that control fatty acid transport, β-oxidation, mi-
tochondrial respiration, and energy uncoupling [22]. Inter-
estingly, Dressel et al. demonstrated that the various PPAR
isotypes regulated diﬀerent metabolic pathways in diﬀeren-
tiated C2C12 cells. They reported that PPARβ/δ controlled
fatty acid catabolism, while PPARα was involved in the con-
trol of fructose uptake and glycogen metabolism, and PPARγ
controlled expression of genes implicated in glucose uptake
and lipid synthesis [39].
Next to these data obtained with cultured myotubes, it
was reported that administration of PPARβ/δ agonist up-
regulated expression of several genes implicated in lipid
metabolism and fatty acid catabolism and reduced lipid con-
tent in mouse skeletal muscle [22].
The demonstration that PPARβ/δ agonists induced fatty
acid burning in muscle, explains, at least partly, the beneﬁ-
cial eﬀects of such treatment in obese animals, as it is well
established that fatty acid catabolism is reduced in muscles
from diabetic and obese animals and that lipid deposition
is leading to insulin resistance, especially in muscle tissues
[1, 36, 37]. Moreover, the generation of transgenic mod-
els for a muscle-speciﬁc overexpression of PPARβ/δ revealed4 PPAR Research
anotherimportantandinterestingfunctionofthenuclearre-
ceptor in muscle physiology that could be very important for
the understanding of the mechanisms implicated in the ben-
eﬁcial eﬀects of PPARβ/δ activation.
3.2. RolesofPPARβ/δ inlipidmetabolismand
adaptiveresponsesofskeletalmuscle
To further investigate the roles of PPARβ/δ in muscle physi-
ology, we have generated an animal model allowing a skeletal
muscle-speciﬁc overexpression of the nuclear receptor [27].
In such an animal model, the PPARβ/δ protein content was
increased by 4- to 6-fold early after birth in all types of
myoﬁbers, that is, oxidative and glycolytic, fast- and slow-
twitch.Histologicalanalysisrevealedthatthenumberoftype
2a myoﬁbers, that is, oxidative fast twitch, was increased in
muscles from PPARβ/δ-overexpressing animals when com-
pared to their control littermates. In tibialis anterior muscle
and, to a lesser extent, in soleus muscle, this remodeling was
due to an increase in total myoﬁber number, with a speciﬁc
increase of type 2a myoﬁbers, while in other muscles, such
as plantaris and EDL, the increase in type 2a myoﬁber num-
b e rw a so n l yd u et oc o n v e r s i o no ft y p e2 bt ot y p e2 am y -
oﬁbers. These observations were conﬁrmed by the demon-
stration that PPARβ/δ overexpression led to increased ex-
pression of genes implicated in fatty acid catabolism, such
as citrate synthase, h-FABP, and UCP-2.
Another group investigated the eﬀects of muscle-speciﬁc
expression of a constitutively active PPARβ/δ (VP16-PP-
ARβ/δ) mutant form. Such animals displayed a more pro-
nounced phenotype characterized by an increase of slow-
twitch myoﬁber number in all types of muscles, including
predominantly fast-twitchmuscles [40].Thediscrepancybe-
tween the two animal models could be due to the fact that
the VP16-PPARβ/δ has a strongest transcriptional activity
and upregulates expression of genes that are not aﬀected by
overexpressionofthewildtypePPARβ/δ.Forinstance,PGC-
1, which plays a crucial role in conversion of fast-twitch to
slow-twitch myoﬁbers [41], is upregulated in muscles from
VP16-PPARβ/δ mice [40]b u ti su n c h a n g e di nm u s c l e sf r o m
PPARβ/δ-overexpressing animals [27]. However, it appeared
that overexpression of either native or constitutively active
PPARβ/δ forms has beneﬁcial metabolic eﬀects in mice by
reducing adiposity, lowering lipid contents in several organs,
and increasing insulin responsiveness [27, 40].
Collectively, these ﬁndings strongly suggested that over-
expression and/or activation of PPARβ/δ mimics the actions
of physical exercise on muscle remodeling and metabolism,
at least in mouse. Several experimental evidences favor the
hypothesis that PPARβ/δ plays a central role in adaptive re-
sponse of skeletal muscle to endurance exercise. Daily mod-
erate swimming exercise promoted PPARβ/δ upregulation
in mouse skeletal muscle [27]. This increased expression re-
quires several weeks of training, while it has been reported
that in human muscle, a similar change in PPARβ/δ mRNA
abundance takes place after shorter exercise period [28].
Moreover, VP16-PPARβ/δ mice display increased resistance
to fatigue and running performance than their control lit-
termates [40]. The molecular mechanisms that lead to the
increased expression of PPARβ/δ in skeletal muscle during
endurance training remain to be elucidated. Similarly, the
molecularandcellulareventsthatlinkthe expressionandac-
tivation levels of PPARβ/δ to myoblast proliferation and ox-
idative ﬁber typing remain to be characterized. However, it
can be proposed that upregulation of the nuclear receptor is
oneoftheﬁrsteventsleadingtochangesintheoxidativeﬁber
number,whileactivationofPPARβ/δ,bynaturalorsynthetic
ligands, controls the degree of conversion of fast-twitch to
slow-twitch phenotype.
4. CONCLUSIONS
During the few past years, the knowledge of physiological
functions of PPARβ/δ has considerably increased and it is
now established that speciﬁc agonists of the nuclear recep-
tor may have therapeutic usefulness in metabolic syndrome.
The actions of PPARβ/δ in skeletal muscle, that is, oxidative
myoﬁber remodeling and increase of fatty acid burning ca-
pacity, may explain the beneﬁcial eﬀects of speciﬁc agonists
on obesity and insulin resistance by limiting substrate avail-
ability for lipid synthesis and accumulation in adipose tis-
sue and other insulin sensitive tissues. The muscle remodel-
ing induced by PPARβ/δ activation may also aﬀect the en-
docrine functions of skeletal muscle. It is now established
that physical exercise is increasing fatty acid burning, but it is
also changing the secretion level of muscle cytokines, called
myokines, that control metabolic responses of other tissues,
including adipose tissue [42]. Further studies are required
to investigate the regulatory functions of PPARβ/δ activa-
tion on myokine production. Future work is also needed to
clarify the roles of PPARβ/δ in other tissues that express the
nuclear receptor at high levels, such as heart, intestine and
brain, in order to prevent any side eﬀects of PPARβ/δ activa-
tion.
Very importantly, level of experimental evidence is still
restrained to animal models and a direct extrapolation of
data obtained with rodent or primate models to the human
contextisriskyastherearegreatdiﬀerencesinmetabolicreg-
ulations between species. Clinical trials have been initiated
and will provide important data regarding eﬃciency, toler-
ance, and safety in human for some PPARβ/δ agonists. The
outcome of such clinical trials is eagerly awaited to conﬁrm
theregulatoryrolesofPPARβ/δ inhumanmusclephysiology
and metabolism.
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